PENTAMIDINE ISETHIONATE

Post-LOE

pentamidine isethionate

Gen Pharmaceuticals

ANDAINHALATIONFOR SOLUTION

Approved

Jan 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PENTAMIDINE ISETHIONATE (pentamidine isethionate) by Gen Pharmaceuticals is mechanism of action studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of dna, rna, phospholipid and protein synthesis. Approved for pneumocystis jiroveci pneumonia (pjp) in high-risk, hiv-infected patients defined by one, both of the following criteria: i. First approved in 2023.

Drug data last refreshed 20h ago

Mechanism of Action

Mechanism of Action Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis. However, the mode of action is not fully understood.

Indications (3)

Pneumocystis jiroveci pneumonia (PJP) in high-risk HIV-infected patients defined by one

Worked on PENTAMIDINE ISETHIONATE at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.